UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005964
Receipt number R000007048
Scientific Title Influence of febuxostat and allopurinol on renal function for hyperuricemia
Date of disclosure of the study information 2011/07/11
Last modified on 2012/12/27 10:41:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Influence of febuxostat and allopurinol on renal function for hyperuricemia

Acronym

Influence of afebuxostat and allopurinol on renal function for hyperuricemia

Scientific Title

Influence of febuxostat and allopurinol on renal function for hyperuricemia

Scientific Title:Acronym

Influence of afebuxostat and allopurinol on renal function for hyperuricemia

Region

Japan


Condition

Condition

Hyperuricemic patients (Uric acid>8.0mg/dL)

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of present study is to evaluate the urate-lowering efficacy and renal function of febuxostat and allopurinoln.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) Serum uric acid
2) Urinary Albumin

Key secondary outcomes

1) serum Cr
2) eGFR
3) cystatin C
4) Oxidized LDL
5) T-cho, TG, LDL,HDL
6)PWV
7)BNP, EF, LVM
8) side effects


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Febuxostat group: The patients was treated by 10 mg/day of febuxostat and controlled Uric acid less than 6mg/dl/ (maximum 60 mg/day of febuxostat)

Interventions/Control_2

Allopurinol group: The patients was treated by 100 mg/day of allopurinol and controlled Uric acid less than 6mg/dl/ (maximum 300 mg/day of febuxostat)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Serum Uric acid>8.0mg/dl
Patients from whom informed consent was obtained

Key exclusion criteria

The patients who are contraindicated to use febuxostat or allopurinol.
Patients who do not agree and whom physician judges inappropriate to this trial for any reason

Target sample size

140


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akira Sezai

Organization

Nihon University School of Medicine

Division name

Department of Cardiovascular Surgery

Zip code


Address

30-1 Oyaguchi kami-machi, Itabashi-ku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Nihon University School of Medicine

Division name

Department of Cardiovascular Surgery

Zip code


Address


TEL


Homepage URL


Email

asezai.med@gmail.com


Sponsor or person

Institute

Nihon University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Sekino Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本大学医学部附属板橋病院(東京都)、関野病院(東京都)


Other administrative information

Date of disclosure of the study information

2011 Year 07 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 05 Month 01 Day

Last follow-up date

2012 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 07 Month 11 Day

Last modified on

2012 Year 12 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007048


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name